These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 18311541

  • 21. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
    Tran H, Brighton T, Grigg A, McRae S, Dixon J, Thurley D, Gandhi MK, Truman M, Marlton P, Catalano J.
    Br J Haematol; 2014 Oct; 167(2):243-51. PubMed ID: 25041261
    [Abstract] [Full Text] [Related]

  • 22. Management of patients with refractory immune thrombocytopenic purpura.
    George JN.
    J Thromb Haemost; 2006 Aug; 4(8):1664-72. PubMed ID: 16879206
    [Abstract] [Full Text] [Related]

  • 23. [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura].
    Wang W, Yu QH, Zhang HY, Chu XX, Chen F, Zhang CQ, Zhou YH, Hou M.
    Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):225-7. PubMed ID: 18785508
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Successful treatment with rituximab of refractory idiopathic thrombocytopenic purpura in a patient with Kabuki syndrome.
    Torii Y, Yagasaki H, Tanaka H, Mizuno S, Nishio N, Muramatsu H, Hama A, Takahashi Y, Kojima S.
    Int J Hematol; 2009 Sep; 90(2):174-176. PubMed ID: 19662467
    [Abstract] [Full Text] [Related]

  • 26. Rituximab for the treatment of acute refractory ITP.
    Kim SG, Whyte D, Pashankar FD.
    J Pediatr Hematol Oncol; 2014 Apr; 36(3):e149-51. PubMed ID: 23669737
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Rituximab is effective for selected patients with chronic steroid-refractory immune thrombocytopenic purpura.
    Lalayanni C, Stavroyianni N, Saloum R, Tsompanakou A, Anagnostopoulos A.
    Hematology; 2004 Aug; 9(4):287-9. PubMed ID: 15621736
    [Abstract] [Full Text] [Related]

  • 30. Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab).
    Narang M, Penner JA, Williams D.
    Am J Hematol; 2003 Dec; 74(4):263-7. PubMed ID: 14635207
    [Abstract] [Full Text] [Related]

  • 31. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.
    Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG.
    Ann Intern Med; 2007 Jan 02; 146(1):25-33. PubMed ID: 17200219
    [Abstract] [Full Text] [Related]

  • 32. [Clinical therapeutic efficacy of rituximab for relapsed and refractory idiopathic thrombocytopenic purpura].
    Zhou LY, Zhang Z, Song LX, Gzhang X, Su JY, Li X, Chang CK.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug 02; 20(4):941-4. PubMed ID: 22931660
    [Abstract] [Full Text] [Related]

  • 33. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia.
    Hegde UP, Wilson WH, White T, Cheson BD.
    Blood; 2002 Sep 15; 100(6):2260-2. PubMed ID: 12200396
    [Abstract] [Full Text] [Related]

  • 34. [Clinical efficacy of lower dose rituximab for chronic refractory immune thrombocytopenic purpura].
    Li Y, Wang XM, Mao M, Zhang XY, Fu L, Ai HM, Zhang LX.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar 15; 33(3):204-6. PubMed ID: 22781608
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.
    Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB.
    Br J Haematol; 2004 Apr 15; 125(2):232-9. PubMed ID: 15059147
    [Abstract] [Full Text] [Related]

  • 38. Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience.
    Al Askar AS, Shaheen NA, Al Zahrani M, Al Otaibi MG, Al Qahtani BS, Ahmed F, Al Zughaibi M, Kamran I, Mendoza MA, Khan A.
    Int J Hematol; 2018 Jan 15; 107(1):69-74. PubMed ID: 28895035
    [Abstract] [Full Text] [Related]

  • 39. Emerging strategies to treat chronic immune thrombocytopenic purpura.
    Newland A.
    Eur J Haematol Suppl; 2008 Feb 15; (69):27-33. PubMed ID: 18211570
    [Abstract] [Full Text] [Related]

  • 40. Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura.
    Vancine-Califani SM, De Paula EV, Ozelo MC, Orsi FL, Fabri DR, Annichino-Bizzacchi JM.
    Platelets; 2008 Nov 15; 19(7):489-95. PubMed ID: 18979360
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.